Inogen Inc

NASDAQ:INGNUnited States

Nov 7, 2024

Show headlines and story abstract

• -- Earnings Flash (INGN) INOGEN Posts Q3 Revenue $88.8M, from 4:16PM ET on Thursday Nov 07, 2024 by MT Newswires

  4:16PM ET on Thursday Nov 07, 2024 by MT Newswires
  Companies Mentioned: INGN
  04:16 PM EST, 11/07/2024 (MT Newswires) -- ...

• Inogen Announces Third Quarter 2024 Financial Results, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones

  4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: INGN
  Payment of employment taxes related to release of restricted stock (286) (504) ------- ------- Net cash provided by financing activities 525 974 ------- ------- Effect of exchange rates on cash (153) 149 ------- ------- Net decrease in cash, cash equivalents and restricted cash $(16,211) $(62,406) ------- ------- Supplemental Financial Information (unaudited) (in thousands, except units and patients) Constant Three months ended Currency September 30, Change 2024 vs. 2023 Change ------------------ -------------------- ---------- Revenue by region and category 2024 2023 $ % % ---------------------- -------- -------- --------- --------- ---------- Business-to-business domestic sales $ 23,352 $ 17,288 $ 6,064 35.1% 35.1% Business-to-business international sales 32,328 25,613 6,715 26.2% 26.9% Direct-to-consumer domestic sales 19,249 25,072 (5,823) -23.2% -23.2% Direct-to-consumer domestic rentals 13,905 15,994 (2,089) -13.1% -13.1% ------- ------- ------- ----- ------ Total revenue $ 88,834 $ 83,967 $ 4,867 5.8% 6.0% ======= ======= ======= ===== ====== Additional financial measures Units Sold 43,900 35,400 Net rental patients as of period-end 51,400 51,900 Constant Nine months ended Currency September 30, Change 2024 vs. 2023 Change ------------------ -------------------- ---------- Revenue by region and category 2024 2023 $ % % ---------------------- -------- -------- --------- --------- ---------- Business-to-business domestic sales $ 61,158 $ 48,145 $ 13,013 27.0% 27.0% Business-to-business international sales 88,894 67,877 21,017 31.0% 30.8% Direct-to-consumer domestic sales 62,397 76,181 (13,784) -18.1% -18.1% Direct-to-consumer domestic rentals 43,175 47,561 (4,386) -9.2% -9.2% ------- ------- ------- ----- ------ Total revenue $255,624 $239,764 $ 15,860 6.6% 6.6% ======= ======= ======= ===== ====== Additional financial measures Units Sold 119,100 96,400 Net rental patients as of period-end 51,400 51,900 Reconciliation of U.S. GAAP to Other Non-GAAP Financial Measures (unaudited) (in thousands) Three months ended Nine months ended September 30, September 30, -------------------- ---------------------- Non-GAAP EBITDA and Adjusted EBITDA 2024 2023 2024 2023 ------------------------ --------- --------- --------- ----------- Net loss (GAAP) $ (5,963) $(45,719) $(26,131) $(75,894) Non-GAAP adjustments: Interest income, net (1,041) (1,801) (3,777) (4,972) Provision (benefit) for income taxes (101) 401 (258) 638 Depreciation and amortization 5,314 4,614 15,924 13,008 ------- ------- ------- ------- EBITDA (non-GAAP) (1,791) (42,505) (14,242) (67,220) Stock-based compensation 1,474 1,779 5,704 8,484 Acquisition-related expenses 127 960 784 1,981 Restructuring-related and other charges -- 1,416 -- 3,426 Impairment charges -- 32,894 -- 32,894 Change in fair value of earnout liability 650 -- 1,830 -- ------- ------- ------- ------- Adjusted EBITDA (non-GAAP) $ 460 $ (5,456) $ (5,924) $(20,435) ======= ======= ======= ======= Three months ended September 30, -------------------------------------------- Net Loss Diluted EPS -------------------- ---------------------- Non-GAAP Adjusted Net Loss and Diluted EPS 2024 2023 2024 2023 ------------------------ --------- --------- --------- ----------- Financial Results (GAAP) $ (5,963) $(45,719) $ (0.25) $ (1.97) Non-GAAP adjustments: Amortization of intangibles 1,107 205 Stock-based compensation 1,474 1,779 Acquisition-related expenses 127 960 Restructuring-related and other charges (1) -- 1,416 Impairment charges -- 32,894 Change in fair value of earnout liability 650 -- Income tax impact of adjustments (2) -- -- ------- ------- --------- ----------- Adjusted $ (2,605) $ (8,465) $ (0.11) $ (0.36) ======= ======= ======= ======= Nine months ended September 30, -------------------------------------------- Net Loss Diluted EPS -------------------- ---------------------- Non-GAAP Adjusted Net Loss and Diluted EPS 2024 2023 2024 2023 ------------------------ --------- --------- --------- ----------- Financial Results (GAAP) $(26,131) $(75,894) $ (1.11) $ (3.28) Non-GAAP adjustments: Amortization of intangibles 3,227 284 Stock-based compensation 5,704 8,484 Acquisition-related expenses 784 1,981 Restructuring-related and other charges (1) -- 3,426 Impairment charges -- 32,894 Change in fair value of earnout liability 1,830 -- Income tax impact of adjustments (2) -- -- ------- ------- --------- ----------- Adjusted $(14,586) $(28,825) $ (0.62) $ (1.25) ======= ======= ======= ======= (1) Charges represent the costs associated with workforce reductions and other restructuring-related activities. (2) Income tax impact of adjustments represents the tax impact related to the non-GAAP adjustments listed above and reflects an effective tax rate of 0% for the three and nine months ended September 30, 2024 and 2023.
  

• *DJ Inogen 3Q Loss/Shr 25c >INGN, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones

  4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: INGN
  Payment of employment taxes related to release of restricted stock (286) (504) ------- ------- Net cash provided by financing activities 525 974 ------- ------- Effect of exchange rates on cash (153) 149 ------- ------- Net decrease in cash, cash equivalents and restricted cash $(16,211) $(62,406) ------- ------- Supplemental Financial Information (unaudited) (in thousands, except units and patients) Constant Three months ended Currency September 30, Change 2024 vs. 2023 Change ------------------ -------------------- ---------- Revenue by region and category 2024 2023 $ % % ---------------------- -------- -------- --------- --------- ---------- Business-to-business domestic sales $ 23,352 $ 17,288 $ 6,064 35.1% 35.1% Business-to-business international sales 32,328 25,613 6,715 26.2% 26.9% Direct-to-consumer domestic sales 19,249 25,072 (5,823) -23.2% -23.2% Direct-to-consumer domestic rentals 13,905 15,994 (2,089) -13.1% -13.1% ------- ------- ------- ----- ------ Total revenue $ 88,834 $ 83,967 $ 4,867 5.8% 6.0% ======= ======= ======= ===== ====== Additional financial measures Units Sold 43,900 35,400 Net rental patients as of period-end 51,400 51,900 Constant Nine months ended Currency September 30, Change 2024 vs. 2023 Change ------------------ -------------------- ---------- Revenue by region and category 2024 2023 $ % % ---------------------- -------- -------- --------- --------- ---------- Business-to-business domestic sales $ 61,158 $ 48,145 $ 13,013 27.0% 27.0% Business-to-business international sales 88,894 67,877 21,017 31.0% 30.8% Direct-to-consumer domestic sales 62,397 76,181 (13,784) -18.1% -18.1% Direct-to-consumer domestic rentals 43,175 47,561 (4,386) -9.2% -9.2% ------- ------- ------- ----- ------ Total revenue $255,624 $239,764 $ 15,860 6.6% 6.6% ======= ======= ======= ===== ====== Additional financial measures Units Sold 119,100 96,400 Net rental patients as of period-end 51,400 51,900 Reconciliation of U.S. GAAP to Other Non-GAAP Financial Measures (unaudited) (in thousands) Three months ended Nine months ended September 30, September 30, -------------------- ---------------------- Non-GAAP EBITDA and Adjusted EBITDA 2024 2023 2024 2023 ------------------------ --------- --------- --------- ----------- Net loss (GAAP) $ (5,963) $(45,719) $(26,131) $(75,894) Non-GAAP adjustments: Interest income, net (1,041) (1,801) (3,777) (4,972) Provision (benefit) for income taxes (101) 401 (258) 638 Depreciation and amortization 5,314 4,614 15,924 13,008 ------- ------- ------- ------- EBITDA (non-GAAP) (1,791) (42,505) (14,242) (67,220) Stock-based compensation 1,474 1,779 5,704 8,484 Acquisition-related expenses 127 960 784 1,981 Restructuring-related and other charges -- 1,416 -- 3,426 Impairment charges -- 32,894 -- 32,894 Change in fair value of earnout liability 650 -- 1,830 -- ------- ------- ------- ------- Adjusted EBITDA (non-GAAP) $ 460 $ (5,456) $ (5,924) $(20,435) ======= ======= ======= ======= Three months ended September 30, -------------------------------------------- Net Loss Diluted EPS -------------------- ---------------------- Non-GAAP Adjusted Net Loss and Diluted EPS 2024 2023 2024 2023 ------------------------ --------- --------- --------- ----------- Financial Results (GAAP) $ (5,963) $(45,719) $ (0.25) $ (1.97) Non-GAAP adjustments: Amortization of intangibles 1,107 205 Stock-based compensation 1,474 1,779 Acquisition-related expenses 127 960 Restructuring-related and other charges (1) -- 1,416 Impairment charges -- 32,894 Change in fair value of earnout liability 650 -- Income tax impact of adjustments (2) -- -- ------- ------- --------- ----------- Adjusted $ (2,605) $ (8,465) $ (0.11) $ (0.36) ======= ======= ======= ======= Nine months ended September 30, -------------------------------------------- Net Loss Diluted EPS -------------------- ---------------------- Non-GAAP Adjusted Net Loss and Diluted EPS 2024 2023 2024 2023 ------------------------ --------- --------- --------- ----------- Financial Results (GAAP) $(26,131) $(75,894) $ (1.11) $ (3.28) Non-GAAP adjustments: Amortization of intangibles 3,227 284 Stock-based compensation 5,704 8,484 Acquisition-related expenses 784 1,981 Restructuring-related and other charges (1) -- 3,426 Impairment charges -- 32,894 Change in fair value of earnout liability 1,830 -- Income tax impact of adjustments (2) -- -- ------- ------- --------- ----------- Adjusted $(14,586) $(28,825) $ (0.62) $ (1.25) ======= ======= ======= ======= (1) Charges represent the costs associated with workforce reductions and other restructuring-related activities. (2) Income tax impact of adjustments represents the tax impact related to the non-GAAP adjustments listed above and reflects an effective tax rate of 0% for the three and nine months ended September 30, 2024 and 2023.
  

• Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations, from 4:04PM ET on Thursday Nov 07, 2024 by Dow Jones

  4:04PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: SGHT, INGN
  
  release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.